BioTek Synergy™ 2 and Synergy™4 Validated for Use with Transcreener Technology

BellBrook Labs has announced that the BioTek Synergy™ 2 and Synergy™4, fluorescence polarization instruments are now validated for use with the Transcreener Platform.

BellBrook Labs has designed an instrument validation program in an effort to align the high standards of the Transcreener Assay with frequently used instrument platforms.

The program is a part of a BellBrook initiative to maximize customer success with using Transcreener Assays as quickly and efficiently as possible. BellBrook scientists personally test each instrument line and are able to assure customers that the instrument will perform well with BellBrook’s far red FP assays across a broad range of specific criteria.

BioTek Synergy™ 2 and 4 did meet the validation criteria and BellBrook now offers a detailed guideline for setting up and using the BioTek instrument specifically with Transcreener Assays.

“BellBrook’s primary goal is to accelerate the discovery of innovative new therapies for debilitating diseases. The Transcreenera Platform has already made a big impact by enabling our customers to screen a very diverse collection of promising, yet challenging targets,” Comments Robert Lowery, CEO of BellBrook Labs.

“Making this capability broadly accessible requires straightforward implementation on the major instrument platforms, and our partnership with BioTek is a major step in this direction."